Pelthos Therapeutics Files 8-K on Shareholder Votes
Ticker: PTHS · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1919246
| Field | Detail |
|---|---|
| Company | Pelthos Therapeutics Inc. (PTHS) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing-update
TL;DR
Pelthos Therapeutics filed an 8-K on 12/17/25 regarding shareholder votes. Big decisions ahead.
AI Summary
Pelthos Therapeutics Inc. filed an 8-K on December 17, 2025, to report on matters submitted to a vote of its security holders. The company, formerly known as Channel Therapeutics Corp and Chromocell Therapeutics Corp, is incorporated in Nevada and operates in the biological products sector.
Why It Matters
This filing indicates important corporate actions or decisions are being made that could affect shareholders and the company's strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not an event that inherently increases risk.
Key Players & Entities
- Pelthos Therapeutics Inc. (company) — Registrant
- Channel Therapeutics Corp (company) — Former Company Name
- Chromocell Therapeutics Corp (company) — Former Company Name
- December 17, 2025 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of Pelthos Therapeutics Inc. security holders?
The filing states that it is a report on 'Submission of Matters to a Vote of Security Holders', but the specific details of the matters voted upon are not included in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported is December 17, 2025, which is also the date of the report.
What is the principal executive office address for Pelthos Therapeutics Inc.?
The principal executive office is located at 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703.
What were the previous names of Pelthos Therapeutics Inc.?
Pelthos Therapeutics Inc. was formerly known as Channel Therapeutics Corp and prior to that, Chromocell Therapeutics Corp.
In which state is Pelthos Therapeutics Inc. incorporated?
Pelthos Therapeutics Inc. is incorporated in Nevada.
Filing Stats: 774 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2025-12-17 16:15:56
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PTHS The NYSE American LL
Filing Documents
- g085048_8k.htm (8-K) — 50KB
- 0001753926-25-001906.txt ( ) — 214KB
- pths-20251217.xsd (EX-101.SCH) — 3KB
- pths-20251217_lab.xml (EX-101.LAB) — 33KB
- pths-20251217_pre.xml (EX-101.PRE) — 22KB
- g085048_8k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On December 17, 2025, Pelthos Therapeutics Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). Set forth below are the three proposals that were voted on at the Annual Meeting and the stockholder votes on each such proposal, as certified by the inspector of elections for the Annual Meeting. These proposals are described in further detail in the Definitive Proxy Statement on Schedule 14A filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") on November 25, 2025 (the "Proxy Statement"). As of the close of business on November 24, 2025, the record date for the Annual Meeting, 3,086,681 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), were issued, outstanding and entitled to vote. Holders of shares of Common Stock were entitled to one vote per share for each share of Common Stock. Stockholders holding an aggregate of 2,528,857 votes were present at the Annual Meeting, in person or represented by proxy, which number constituted a quorum. Proposal 1 - The seven (7) nominees named in the Proxy Statement were elected at the Annual Meeting to serve as the Company's directors until the Company's 2026 Annual Meeting of Stockholders and until each of their respective successors are elected and qualified or until each of their earlier resignation or removal. The final voting results with respect to the election of each such nominee were as follows: Nominee For Withheld Peter Greenleaf 2,250,631 92 Richard Baxter 2,250,670 53 Todd Davis 2,249,001 1,722 Ezra Friedberg 2,250,670 53 Dr. Richard Malamut 2,250,171 552 Matthew Pauls 2,248,962 1,761 Scott Plesha 2,250,426 297 There were 278,134 broker non-votes with respect to each such nominee for the first proposal. Proposal 2 - The proposal to waive the limit on the number of shares of Common Stock that may be issue
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 17, 2025 Pelthos Therapeutics Inc. By: /s/ Francis Knuettel II Name: Francis Knuettel II Title: Chief Financial Officer